Improvement in glycemic control over 11 years in patients monitored for diabetes in one county

Clinical Chemistry and Laboratory Medicine

Volumn 44, Issue 1, 2006, Pages 92-98

  Jørgensen, Lone G M ^a,e   Petersen, Per Hyltoft ^b   Christensen, Cramer ^a   Eriksen, Ebbe Wendel ^c   Brandslund, Ivan ^a,d  

^a LILLEBAELT HOSPITAL   (Denmark)

^b UNIVERSITY OF BERGEN   (Norway)

^c General Practice Office   (Denmark)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^e NONE   (Denmark)

Author keywords

Clinical outcome; Glycated hemoglobin A1c (HbA1c); Prognosis

Indexed keywords

HEMOGLOBIN A1C;

ADOLESCENT; ADULT; AGED; ANALYTIC METHOD; ARTICLE; CHILD; CONTROLLED STUDY; DIABETES CONTROL; DIABETES MELLITUS; FEMALE; HEMOCONCENTRATION; HEMOGLOBIN DETERMINATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PATIENT MONITORING; POPULATION; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CHILD; DENMARK; DIABETES MELLITUS; FEMALE; HEMOGLOBIN A; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; RETROSPECTIVE STUDIES; RISK REDUCTION BEHAVIOR; SENSITIVITY AND SPECIFICITY; SEX CHARACTERISTICS; TIME FACTORS; TREATMENT OUTCOME;

EID: 29444456063     PISSN: 14346621     EISSN: 14346621     Source Type: Journal    
DOI: 10.1515/CCLM.2006.018     Document Type: Article

References (26)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
2. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complication trial. Diabetes 1995;44:969-83.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
4. Stratton IM, Adler A, Neil HAW, Matthews D, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000;321:405-12.
5. Khaw K-T, Wareham N, Lubin R, Bingham S, Oakes S, Welch A, et al. Glucated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). Br Med J 2001;322:15-8.
6. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17.
7. The American Medical Association (AMA), The Joint Commission on Accreditation of Healthcare Organizations (JCAHO), and The National Committee for Quality Assurance (NCQA). Coordinated performance measurement for the management of adult diabetes. http://www.ama-assn.org/ama/pub/article/2403-4583. html.
8. European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes. Diabet Med 1999;16:716-30 (http://www.staff.ncl.ac.uk/philip.home/t2dg1999. htm#H).
9. Jeffcoate SL. Diabetes control and complications: the role of glycated haemoglobin, 25 years on. Diabet Med 2003;21:657-65.
10. StatBank Denmark, populations and elections (BEF1A). Copenhagen, Denmark: Statistics Denmark, 2005.
11. Jørgensen LG, Brandslund I, Stahl M, Hyltoft Petersen P, Iversen S, Klitgaard N, et al. Upper reference limit, analytical quality specifications and clinical use of haemoglobin A1c. Scand J Clin Lab Invest 2002;62:609-22.
12. Hyltoft Petersen P, Blaabjerg O, Andersen M, Jørgensen LG, Schousboe K, Jensen E. Graphical interpretation of confidence curves in rankit plots. Clin Chim Lab Med 2004;42:715-24.
13. Jørgensen LG, Løber J, Carlsen NLT, Momsen G, Hirsch F. Serum neuron specific enolase (S-NSE) reference interval evaluation by time-resolved immunofluorometry compared with a radioimmunoassay. Clin Chim Acta 1996;249:77-91.
14. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurements. Lancet 1986:1;307-10.
15. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. J Am Med Assoc 2001;286:1195-200.
16. Steffes M, Cleary P, Goldstein D, Little R, Wiedmeyer HM, Rohlfing C, et al. Haemoglobin A1c measurements over nearly two decades: sustaining comparable values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study. Clin Chem 2005;51:753-8.
17. World Health Organization. Screening for type 2 diabetes. Report of a World Health Organization and International Diabetes Federation meeting. Geneva, Switzerland: WHI, 20022 (http://www.who.int/ncd/dia/screening_mnc03.pdf).
18. McCance DR, Hanson RL, Pettitt DJ, Bennett PH, Hadden DR, Knowler WC. Diagnosing diabetes mellitus - do we need new criteria? Diabetologia 1997;40:247-55.
19. Alberti KG, Gries FA, Jervell J, Krans HM. A desktop guide for the management of non-insulin-dependent diabetes mellitus (NIDDM): an update. Diabet Med 1994;11:899-909.
20. Hoelzel W, Weykamp C, Jeppsson JO, Miedema K, Barr JR, Goodall I, et al. IFCC Working Group on HbA1c Standardization. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 2004;50:166-74.
21. Jørgensen LG, Hyltoft Petersen P, Brandslund I. The impact of variability in the risk of disease exemplified by diagnosing diabetes mellitus based on ADA and WHO criteria as gold standard. International Journal of Risk Assessment and Management (IJRAM) 2005;5:358-73.
22. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al., for The Finnish Diabetes Prevention Study group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
23. Borch-Johnsen K. Forebyggelse af en folkesygdom og dens konsekvenser. Ugeskr Laeger 2004;166:1316-20.
24. National Board of Health. Diabetes i Danmark. Metodeudvikling til en registerbaseret vurdering af diabetes-forkomst. Copenhagen, Denmark: National Board of Health, 2001 (http://www.sst.dk/nyheder/tidsskrifter/nyetal/pdf/ nyetal5_8.pdf).
25. Gale EA. Is there really an epidemic of type 2 diabetes? Lancet 2003;362:503-4.
26. Jørgensen LG, Brandslund I, Hyltoft Petersen P, de Fine Olivarius N, Stahl M. The effect of the new ADA and WHO guidelines on the number of diagnosed diabetes mellitus cases. Clin Chem Lab Med 2003;41:1246-50.